anti-SEZ6/anti-CD276 bispecific ADC(Biocytogen Pharmaceuticals)

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug Nameanti-SEZ6/anti-CD276 bispecific ADC(Biocytogen Pharmaceuticals)
Drug Alias Nameanti-SEZ6/CD276 bispecific ADC(Biocytogen Pharmaceuticals)anti-SEZ6/B7-H3 bispecific ADC(Biocytogen Pharmaceuticals)anti-SEZ6/anti-B7-H3 bispecific ADC(Biocytogen Pharmaceuticals)BCG027BCG-027
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Seizure protein 6 homologAnti-CD276
TargetsSeizure protein 6 homologCD276 antigen
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A